BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 8113668)

  • 1. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.
    Bakker AB; Schreurs MW; de Boer AJ; Kawakami Y; Rosenberg SA; Adema GJ; Figdor CG
    J Exp Med; 1994 Mar; 179(3):1005-9. PubMed ID: 8113668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
    Kawakami Y; Eliyahu S; Delgado CH; Robbins PF; Sakaguchi K; Appella E; Yannelli JR; Adema GJ; Miki T; Rosenberg SA
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6458-62. PubMed ID: 8022805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL.
    Adema GJ; Bakker AB; de Boer AJ; Hohenstein P; Figdor CG
    Br J Cancer; 1996 May; 73(9):1044-8. PubMed ID: 8624261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line.
    Bakker AB; Schreurs MW; Tafazzul G; de Boer AJ; Kawakami Y; Adema GJ; Figdor CG
    Int J Cancer; 1995 Jul; 62(1):97-102. PubMed ID: 7541395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
    Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
    J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
    Anichini A; Maccalli C; Mortarini R; Salvi S; Mazzocchi A; Squarcina P; Herlyn M; Parmiani G
    J Exp Med; 1993 Apr; 177(4):989-98. PubMed ID: 8459226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
    Kawakami Y; Zakut R; Topalian SL; Stötter H; Rosenberg SA
    J Immunol; 1992 Jan; 148(2):638-43. PubMed ID: 1729379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
    Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
    J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.
    Anichini A; Mortarini R; Maccalli C; Squarcina P; Fleischhauer K; Mascheroni L; Parmiani G
    J Immunol; 1996 Jan; 156(1):208-17. PubMed ID: 8598464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
    Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
    J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
    Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
    J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
    Robbins PF; El-Gamil M; Li YF; Zeng G; Dudley M; Rosenberg SA
    J Immunol; 2002 Nov; 169(10):6036-47. PubMed ID: 12421991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A peptide derived from melanocytic protein gp100 and presented by HLA-B35 is recognized by autologous cytolytic T lymphocytes on melanoma cells.
    Vigneron N; Ooms A; Morel S; Ma W; Degiovanni G; Van den Eynde BJ
    Tissue Antigens; 2005 Feb; 65(2):156-62. PubMed ID: 15713214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.
    Schendel DJ; Gansbacher B; Oberneder R; Kriegmair M; Hofstetter A; Riethmüller G; Segurado OG
    J Immunol; 1993 Oct; 151(8):4209-20. PubMed ID: 8409397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.